Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Says European Patent Office grants European patent (EP4114476) for its decellularisation technology, dCELL. The patent relates to the method for producing decellularisation tissue scaffold which is a foundation for Tissue Regenix’s platform and plays a pivotal role in the development of its product range. This patent adds to those the company already has granted in the US and UK for dCELL.
The dCELL platform removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold, which supports tissue growth and remodeling, is not rejected by the patient’s body, and can then be used to repair diseased or damaged body parts.
Chief Executive Daniel Lee says: ‘Securing this patent is a significant achievement for the company. It reflects the continuation of the strength of our innovation and the differentiated value we bring to the market.’
Current stock price: 36.00 pence, unchanged in London on Thursday
12-month change: down 43%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
